Literature DB >> 29423971

Two de novo novel mutations in one SHANK3 allele in a patient with autism and moderate intellectual disability.

Wenmiao Zhu1, Jianli Li1, Stella Chen1, Jinglan Zhang1,2, Francesco Vetrini1, Alicia Braxton1, Christine M Eng1,2, Yaping Yang1,2, Fan Xia1,2, Kory L Keller3, Leila Okinaka-Hu3, Chung Lee4, J Lloyd Holder5,6,7, Weimin Bi1,2.   

Abstract

SHANK3 encodes for a scaffolding protein that links neurotransmitter receptors to the cytoskeleton and is enriched in postsynaptic densities of excitatory synapses. Deletions or mutations in one copy of the SHANK3 gene cause Phelan-McDermid syndrome, also called 22q13.3 deletion syndrome, a neurodevelopmental disorder with common features including global developmental delay, absent to severely impaired language, autistic behavior, and minor dysmorphic features. By whole exome sequencing, we identified two de novo novel variants including one frameshift pathogenic variant and one missense variant of unknown significance in a 14-year-old boy with delayed motor milestones, delayed language acquisition, autism, intellectual disability, ataxia, progressively worsening spasticity of the lower extremities, dysmorphic features, short stature, microcephaly, failure to thrive, chronic constipation, intrauterine growth restriction, and bilateral inguinal hernias. Both changes are within the CpG island in exon 21, separated by a 375 bp sequence. Next generation sequencing of PCR products revealed that the two variants are most frequently associated with each other. Sanger sequencing of the cloned PCR products further confirmed that both changes were on a single allele. The clinical presentation in this individual is consistent with other patients with a truncating mutation in exon 21, suggesting that the missense change contributes none or minimally to the phenotypes. This is the first report of two de novo mutations in one SHANK3 allele.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Phelan-McDermid syndrome; SHANK3; de novo; double mutations on one allele; variant phasing; whole exome sequencing

Mesh:

Substances:

Year:  2018        PMID: 29423971      PMCID: PMC5956516          DOI: 10.1002/ajmg.a.38622

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  18 in total

Review 1.  Synapse structure: glutamate receptors connected by the shanks.

Authors:  M D Ehlers
Journal:  Curr Biol       Date:  1999-11-18       Impact factor: 10.834

2.  Two de novo mutations in the AR gene cause the complete androgen insensitivity syndrome in a pair of monozygotic twins.

Authors:  Nigel P Mongan; Jarmo Jääskeläinen; Katherine Green; John W Schwabe; Naoto Shimura; Mehul Dattani; Ieuan A Hughes
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

3.  De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia.

Authors:  Julie Gauthier; Nathalie Champagne; Ronald G Lafrenière; Lan Xiong; Dan Spiegelman; Edna Brustein; Mathieu Lapointe; Huashan Peng; Mélanie Côté; Anne Noreau; Fadi F Hamdan; Anjené M Addington; Judith L Rapoport; Lynn E Delisi; Marie-Odile Krebs; Ridha Joober; Ferid Fathalli; Fayçal Mouaffak; Ali P Haghighi; Christian Néri; Marie-Pierre Dubé; Mark E Samuels; Claude Marineau; Eric A Stone; Philip Awadalla; Philip A Barker; Salvatore Carbonetto; Pierre Drapeau; Guy A Rouleau
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Double mutant fibrillin-1 (FBN1) allele in a patient with neonatal Marfan syndrome.

Authors:  M Wang; P Kishnani; M Decker-Phillips; S G Kahler; Y T Chen; M Godfrey
Journal:  J Med Genet       Date:  1996-09       Impact factor: 6.318

5.  Frequency and Complexity of De Novo Structural Mutation in Autism.

Authors:  William M Brandler; Danny Antaki; Madhusudan Gujral; Amina Noor; Gabriel Rosanio; Timothy R Chapman; Daniel J Barrera; Guan Ning Lin; Dheeraj Malhotra; Amanda C Watts; Lawrence C Wong; Jasper A Estabillo; Therese E Gadomski; Oanh Hong; Karin V Fuentes Fajardo; Abhishek Bhandari; Renius Owen; Michael Baughn; Jeffrey Yuan; Terry Solomon; Alexandra G Moyzis; Michelle S Maile; Stephan J Sanders; Gail E Reiner; Keith K Vaux; Charles M Strom; Kang Zhang; Alysson R Muotri; Natacha Akshoomoff; Suzanne M Leal; Karen Pierce; Eric Courchesne; Lilia M Iakoucheva; Christina Corsello; Jonathan Sebat
Journal:  Am J Hum Genet       Date:  2016-03-24       Impact factor: 11.025

6.  Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders.

Authors:  Luigi Boccuto; Maria Lauri; Sara M Sarasua; Cindy D Skinner; Daniela Buccella; Alka Dwivedi; Daniela Orteschi; Julianne S Collins; Marcella Zollino; Paola Visconti; Barb Dupont; Danilo Tiziano; Richard J Schroer; Giovanni Neri; Roger E Stevenson; Fiorella Gurrieri; Charles E Schwartz
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

7.  Molecular findings among patients referred for clinical whole-exome sequencing.

Authors:  Yaping Yang; Donna M Muzny; Fan Xia; Zhiyv Niu; Richard Person; Yan Ding; Patricia Ward; Alicia Braxton; Min Wang; Christian Buhay; Narayanan Veeraraghavan; Alicia Hawes; Theodore Chiang; Magalie Leduc; Joke Beuten; Jing Zhang; Weimin He; Jennifer Scull; Alecia Willis; Megan Landsverk; William J Craigen; Mir Reza Bekheirnia; Asbjorg Stray-Pedersen; Pengfei Liu; Shu Wen; Wendy Alcaraz; Hong Cui; Magdalena Walkiewicz; Jeffrey Reid; Matthew Bainbridge; Ankita Patel; Eric Boerwinkle; Arthur L Beaudet; James R Lupski; Sharon E Plon; Richard A Gibbs; Christine M Eng
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

8.  Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms.

Authors:  H L Wilson; A C C Wong; S R Shaw; W-Y Tse; G A Stapleton; M C Phelan; S Hu; J Marshall; H E McDermid
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

9.  Conserved role of intragenic DNA methylation in regulating alternative promoters.

Authors:  Alika K Maunakea; Raman P Nagarajan; Mikhail Bilenky; Tracy J Ballinger; Cletus D'Souza; Shaun D Fouse; Brett E Johnson; Chibo Hong; Cydney Nielsen; Yongjun Zhao; Gustavo Turecki; Allen Delaney; Richard Varhol; Nina Thiessen; Ksenya Shchors; Vivi M Heine; David H Rowitch; Xiaoyun Xing; Chris Fiore; Maximiliaan Schillebeeckx; Steven J M Jones; David Haussler; Marco A Marra; Martin Hirst; Ting Wang; Joseph F Costello
Journal:  Nature       Date:  2010-07-08       Impact factor: 49.962

10.  Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments.

Authors:  Claire S Leblond; Caroline Nava; Anne Polge; Julie Gauthier; Guillaume Huguet; Serge Lumbroso; Fabienne Giuliano; Coline Stordeur; Christel Depienne; Kevin Mouzat; Dalila Pinto; Jennifer Howe; Nathalie Lemière; Christelle M Durand; Jessica Guibert; Elodie Ey; Roberto Toro; Hugo Peyre; Alexandre Mathieu; Frédérique Amsellem; Maria Rastam; I Carina Gillberg; Gudrun A Rappold; Richard Holt; Anthony P Monaco; Elena Maestrini; Pilar Galan; Delphine Heron; Aurélia Jacquette; Alexandra Afenjar; Agnès Rastetter; Alexis Brice; Françoise Devillard; Brigitte Assouline; Fanny Laffargue; James Lespinasse; Jean Chiesa; François Rivier; Dominique Bonneau; Beatrice Regnault; Diana Zelenika; Marc Delepine; Mark Lathrop; Damien Sanlaville; Caroline Schluth-Bolard; Patrick Edery; Laurence Perrin; Anne Claude Tabet; Michael J Schmeisser; Tobias M Boeckers; Mary Coleman; Daisuke Sato; Peter Szatmari; Stephen W Scherer; Guy A Rouleau; Catalina Betancur; Marion Leboyer; Christopher Gillberg; Richard Delorme; Thomas Bourgeron
Journal:  PLoS Genet       Date:  2014-09-04       Impact factor: 5.917

View more
  1 in total

1.  Learning impairments and molecular changes in the brain caused by β-catenin loss.

Authors:  Robert J Wickham; Jonathan M Alexander; Lillian W Eden; Mabel Valencia-Yang; Josué Llamas; John R Aubrey; Michele H Jacob
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.